Incretin receptor ligands, lab models

Research-use notice: This page is a laboratory mechanism note. It is not medical or veterinary advice, and it does not include personal-use steps. BlueNex Labs materials are research use only. Research-use-only labelling is not a Health Canada authorization and it does not create a Drug Identification Number.

Incretin receptor ligand is the class name this catalogue uses for research solids discussed at the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, or the glucagon receptor, plus the amylin-analogue solid that purchasing offices often source beside them. The receptors are different. A binding result at one of them does not document a vial aimed at another. The short definition is the incretin receptor ligand glossary entry. The 2026 reading list is GLP-1 peptide research in 2026.

Four live families

Semaglutide is described in the public literature as a GLP-1 receptor ligand. The shop URL is semaglutide, with more than one milligram fill on that page. Tirzepatide is described as a dual GLP-1 and GIP receptor ligand. The yellow-cap listing is tirzepatide 10 mg. For the black-cap listing, see tirzepatide 30 mg. Retatrutide is described in sponsor trial records as a ligand at the GLP-1, GIP, and glucagon receptors. For the listings, see retatrutide 10 mg, retatrutide 20 mg, and retatrutide 30 mg. Cagrilintide is described as an amylin analogue, at cagrilintide 5 mg. The amylin analogue entry explains why that fourth name is not a GLP-1 sequence. The GLP-1 receptor entry is the receptor definition, not a product page.

The metabolic category hub is the shelf. Milligram size, CAD price, and stock stay on the product URL. This mechanism page does not sell a vial and it does not set a price. If two fills share a product path, they are still different lots when the certificate says so.

What methods papers and trial registries are actually recording

Cell papers in this area report receptor occupancy and second-messenger readouts, often cyclic AMP, in systems that express the receptor named in the method. Sequence changes are discussed as changes in that binding. Public trial registries and sponsor readouts are a second literature. They describe investigational programs. An investigational compound in a sponsor's trial is not a Health Canada authorization for a lyophilized solid, and a readout in that program is not a number on a BlueNex Labs label.

For the retatrutide literature note, see the trial recap. A separate page covers FDA status language. Neither page is an approval announcement. This mechanism page does not repeat clinical endpoints, because those endpoints are not catalogue specifications and because copying them here would blur a research solid with a sponsor program. Use the literature note for the public record. Use the shop page and the lot file for the object you can hold.

Analytical identity is local to the lot

These sequences are long, often modified, and easy to confuse on a cropped chromatogram. How to read a peptide COA still applies: the area percent is purity under the stated HPLC or UPLC method, and the mass is the identity check. Endotoxin is included on some incretin lots and omitted on others. For the library anchors, see retatrutide 10 mg, retatrutide 20 mg, and retatrutide 30 mg. A cap-specific row does not cover a different cap or a different milligram size. Tirzepatide, semaglutide, and cagrilintide need their own anchors when those lots are published.

A semaglutide PDF does not document tirzepatide, even when both names are discussed at the GLP-1 receptor. Receptor overlap is a pharmacology sentence. Lot identity is a sample-name sentence. Write both. The receptor sentence does not replace the sample-name sentence.

Fill size is part of identity

Retatrutide is offered as more than one research fill on one product path. Tirzepatide 10 mg and 30 mg are separate paths. Semaglutide still lists more than one fill on one path. Cagrilintide is a single 5 mg listing. A methods paper that says only the compound name has not specified the fill you received. Write the milligrams next to the receptor sentence. A 10 mg chromatographic area percent is evidence about that 10 mg lot. It is not evidence about a 30 mg vial from a different batch, even when the common name matches. Cap colour, when the library prints it, is a third identifier. Ignore it and you will file the wrong PDF under a convincing title.

Amylin versus GLP-1 is the other split that fill size will not save you from. Cagrilintide can sit in the same parcel as semaglutide. The parcel is one shipment. The lots are two. Certificate of Analysis anchors are per product. Open each one. If a row is missing, leave the cell blank.

Canada procurement without a city doorway

Incretin-class parcels are a frequent customs topic when they move as consumer mail across a border. BlueNex Labs ships inside Canada only, after Interac e-Transfer, on Canada Post Xpresspost. The desk facts are in Canada laboratory procurement. This page does not create a municipal landing for any city. Sold-out sizes remain listed and cannot be added to the cart. Research use only. Not for human or veterinary use.

Modification and fill size are identity, not a class average

Published descriptions discuss semaglutide as a GLP-1 receptor ligand that carries a fatty diacid modification, tirzepatide as a ligand at GLP-1 and GIP receptors, and retatrutide as a ligand at GLP-1, GIP, and glucagon receptors. Cagrilintide is described as a lipidated amylin analogue, not as a GLP-1 sequence. Those sentences name literature classes. They are not measurements of the vial in your hand, and they are not a reason to average a purity figure across the class. A semaglutide area percent does not document tirzepatide. An amylin-analogue file does not document either of them.

Fill size is the second identity line. Retatrutide 10 mg, Retatrutide 20 mg, and Retatrutide 30 mg are separate paths. Tirzepatide 10 mg and Tirzepatide 30 mg are separate paths. Semaglutide still lists more than one fill on one path. Cagrilintide is a single 5 mg listing. A 10 mg report does not document a 30 mg vial. Cap colour, when the library prints it, is a third identifier. Sponsor trial material remains a different object from the lyophilized catalog lot. Use the trial recap for the public record and the shop URL plus the lot file for the object you can hold.

The metabolic category is the shelf. This mechanism page does not set a price and it does not restate a sponsor endpoint as a catalog specification. Research-use only. Not for human or veterinary use.